The new test will help physicians to more accurately identify appropriate drug therapies and dosages for patients. Credit: Tatiana from Pixabay.

Tesis Biosciences has introduced a new predictive genomic assay that will enable physicians to identify suitable drug therapies and dosages for patients across diseases and conditions.

The new pharmacogenomics test will help evaluate the drug metabolism of patients based on their genetic makeup to determine the effectiveness of the drug.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This approach is expected to improve the accuracy of drug therapy and minimise the number of adverse drug reactions while also reducing treatment costs.

Tesis Biosciences chief research officer Divyen Patel said: “It removes the guesswork from deciding which drugs, in which dosage, will be most effective for patients and allows for personalised drug therapies.

“Previously, the dosage has often been decided on criteria no more sophisticated than a patient’s height and weight, often with harmful results.”

The new test has the ability to predict how patients interact with several medications from various classifications, including drugs prescribed to treat common diseases such as diabetes, depression, high blood pressure, cancer and chronic pain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Equipped with a proprietary software platform, the test uses millions of data points to compare a patient’s genetic profile to metabolise or clear particular drug types to make the best therapeutic choice.

The company has already obtained Clinical Laboratory Improvement Amendments certification for the test. It will file an application to receive formal approval for the test from the US Food and Drug Administration.

Patel added: “This test can save millions in healthcare costs by allowing providers to determine from the start which drugs to prescribe and in what dosage, thus avoiding unnecessary and ineffective treatments and medications.”